Tags

Type your tag names separated by a space and hit enter

Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
Am J Manag Care. 2007 Dec; 13 Suppl 10:S270-5.AJ

Abstract

OBJECTIVE

The study compared low-density lipoprotein cholesterol (LDL-C) reduction obtained after switching patients on a statin therapy to rosuvastatin or simvastatin in real-world clinical practice.

METHODS

Using information from an electronic medical records database, for patients >or=18 years of age who received newly prescribed statin therapy during August 2003 to March 2006, who were switched to either rosuvastatin or simvastatin, and who had LDL-C values at baseline, switch and postswitch data were included (N = 277). Percent LDL-C reduction between patients switched to rosuvastatin (n = 155) and those switched to simvastatin (n = 122) were compared. Linear regression model was adjusted for percent LDL-C change from preswitch to switch, LDL-C at time of switch, age, sex, smoking, statin aggressiveness, and therapy duration postswitch. Percent LDL-C reduction for patients switched from atorvastatin to rosuvastatin versus atorvastatin to simvastatin was also compared.

RESULTS

Patients switched to rosuvastatin or simvastatin were similar in age, sex, and baseline LDL-C (mean, 146 mg/dL). Patients switched to rosuvastatin from any other statin had a significantly greater percent LDL-C reduction (18.4%) postswitch than patients switched to simvastatin (5.8%; P = .0003). After adjusting for baseline covariates, rosuvastatin patients had a significantly greater percent LDL-C reduction postswitch than simvastatin patients (16.0% vs 8.8%, respectively; P = .0002). In the subgroup of patients switched from atorvastatin, patients switched to rosuvastatin (n = 67) had a significantly greater adjusted percent LDL-C reduction (13.6%) postswitch than patients switched to simvastatin (5.5%; n = 75; P = .001).

CONCLUSION

Rosuvastatin achieves greater percent LDL-C reduction than simvastatin as a switch therapy in a real-world clinical practice setting. This highlights the need to select the statin to switch to based on additional needed percent LDL-C reduction to meet individual patient targets. Availability of simvastatin (generic statin) and rosuvastatin (branded statin) as treatment options would facilitate efficient and effective management of patients with dyslipidemia.

Authors+Show Affiliations

kathyfox@comcast.netNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

18095777

Citation

Fox, Kathleen M., et al. "Comparison of Low-density Lipoprotein Cholesterol Reduction After Switching Patients On Other Statins to Rosuvastatin or Simvastatin in a Real-world Clinical Practice Setting." The American Journal of Managed Care, vol. 13 Suppl 10, 2007, pp. S270-5.
Fox KM, Gandhi SK, Ohsfeldt RL, et al. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care. 2007;13 Suppl 10:S270-5.
Fox, K. M., Gandhi, S. K., Ohsfeldt, R. L., & Davidson, M. H. (2007). Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. The American Journal of Managed Care, 13 Suppl 10, S270-5.
Fox KM, et al. Comparison of Low-density Lipoprotein Cholesterol Reduction After Switching Patients On Other Statins to Rosuvastatin or Simvastatin in a Real-world Clinical Practice Setting. Am J Manag Care. 2007;13 Suppl 10:S270-5. PubMed PMID: 18095777.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. AU - Fox,Kathleen M, AU - Gandhi,Sanjay K, AU - Ohsfeldt,Robert L, AU - Davidson,Michael H, PY - 2008/1/12/pubmed PY - 2008/1/30/medline PY - 2008/1/12/entrez SP - S270 EP - 5 JF - The American journal of managed care JO - Am J Manag Care VL - 13 Suppl 10 N2 - OBJECTIVE: The study compared low-density lipoprotein cholesterol (LDL-C) reduction obtained after switching patients on a statin therapy to rosuvastatin or simvastatin in real-world clinical practice. METHODS: Using information from an electronic medical records database, for patients >or=18 years of age who received newly prescribed statin therapy during August 2003 to March 2006, who were switched to either rosuvastatin or simvastatin, and who had LDL-C values at baseline, switch and postswitch data were included (N = 277). Percent LDL-C reduction between patients switched to rosuvastatin (n = 155) and those switched to simvastatin (n = 122) were compared. Linear regression model was adjusted for percent LDL-C change from preswitch to switch, LDL-C at time of switch, age, sex, smoking, statin aggressiveness, and therapy duration postswitch. Percent LDL-C reduction for patients switched from atorvastatin to rosuvastatin versus atorvastatin to simvastatin was also compared. RESULTS: Patients switched to rosuvastatin or simvastatin were similar in age, sex, and baseline LDL-C (mean, 146 mg/dL). Patients switched to rosuvastatin from any other statin had a significantly greater percent LDL-C reduction (18.4%) postswitch than patients switched to simvastatin (5.8%; P = .0003). After adjusting for baseline covariates, rosuvastatin patients had a significantly greater percent LDL-C reduction postswitch than simvastatin patients (16.0% vs 8.8%, respectively; P = .0002). In the subgroup of patients switched from atorvastatin, patients switched to rosuvastatin (n = 67) had a significantly greater adjusted percent LDL-C reduction (13.6%) postswitch than patients switched to simvastatin (5.5%; n = 75; P = .001). CONCLUSION: Rosuvastatin achieves greater percent LDL-C reduction than simvastatin as a switch therapy in a real-world clinical practice setting. This highlights the need to select the statin to switch to based on additional needed percent LDL-C reduction to meet individual patient targets. Availability of simvastatin (generic statin) and rosuvastatin (branded statin) as treatment options would facilitate efficient and effective management of patients with dyslipidemia. SN - 1936-2692 UR - https://www.unboundmedicine.com/medline/citation/18095777/Comparison_of_low_density_lipoprotein_cholesterol_reduction_after_switching_patients_on_other_statins_to_rosuvastatin_or_simvastatin_in_a_real_world_clinical_practice_setting_ L2 - https://www.ajmc.com/pubMed.php?pii=6908 DB - PRIME DP - Unbound Medicine ER -